These findings strongly support the specificity of CEA TCB Cibisatamab for targeting CEA-expressing cells, demonstrating its capacity to induce cell death in CEAhigh- and intermediate CEA-expressing tissues, with limited off-tumor cytotoxicity in healthy tissues that express low levels of CEA. The gene discussed is CEACAM3; the disease is neoplasm.